Search
Displaying results 1 - 10 of 12 in total
Secukinumab
go.drugbank.com/drugs/DB09029
ApprovedInvestigational
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive...
Severe Hidradenitis Suppurativa
go.drugbank.com/conditions/DBCOND0020391Moderate Hidradenitis Suppurativa
go.drugbank.com/conditions/DBCOND0020392Bimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigational[A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment
Non-radiographic Axial Spondyloarthritis
go.drugbank.com/conditions/DBCOND0050574Active Ankylosing spondylitis
go.drugbank.com/conditions/DBCOND0020385Drugs: Bimekizumab · Certolizumab pegol · Golimumab · Ixekizumab · Secukinumab · Tofacitinib +1 moreModerate Plaque psoriasis
go.drugbank.com/conditions/DBCOND0020390Drugs: Bimekizumab · Brodalumab · Clobetasol propionate · Deucravacitinib · Etanercept · Guselkumab +3 moreSevere Plaque psoriasis
go.drugbank.com/conditions/DBCOND0025583Drugs: Bimekizumab · Brodalumab · Clobetasol propionate · Deucravacitinib · Etanercept · Guselkumab +3 more